Αποτελέσματα Αναζήτησης
Η μολνουπιραβίρη (molnupiravir) ενδείκνυται για τη θεραπεία της ήπιας έως μέτριας βαρύτητας της νόσου του κορωνοϊού 2019 (COVID-19) σε ενήλικες με θετικό διαγνωστικό τεστ SARS-COV-2 και που έχουν τουλάχιστον έναν παράγοντα κινδύνου για την ανάπτυξη σοβαρής ασθένειας.
13 Σεπ 2024 · The cost of Paxlovid and Lagevrio will depend on whether you have insurance and if you qualify for savings opportunities from the manufacturers. Paxlovid’s average cost for a 5-day treatment course is $ 1585.40. Many insurance plans, including Medicare, cover Paxlovid.
The cost of the US government's initial purchase was about $712 per course of treatment; treatment with generics in developing countries can cost as little as $20. [38] [39] Sales of molnupiravir were $952 million in the fourth quarter of 2021. [40]
19 Νοε 2021 · EMA issued this advice to support national authorities who may decide on possible early use of the medicine prior to marketing authorisation, for example in emergency use settings, in light of rising rates of infection and deaths due to COVID-19 across the EU.
6 Φεβ 2023 · How much does molnupiravir cost? Currently, the U.S. Department of Health and Human Services (HHS) is providing molnupiravir and other COVID-19 treatments at no cost . In March 2022, the Biden administration launched the Test to Treat initiative.
7 Ιουν 2023 · As an emergency-use medication, Lagevrio is currently available at no cost. The only cost would be getting the prescribed medication through a healthcare provider visit, depending on the insurance cost. Although its retail price is not available yet, it is estimated Lagevrio could cost about $700.
1 Οκτ 2021 · How much will the treatment cost? The federal government is paying about $700 per course of treatment. That is about one-third of the cost of a monoclonal antibody treatment.
